SE0201544D0 - Novel compounds and thier use - Google Patents

Novel compounds and thier use

Info

Publication number
SE0201544D0
SE0201544D0 SE0201544A SE0201544A SE0201544D0 SE 0201544 D0 SE0201544 D0 SE 0201544D0 SE 0201544 A SE0201544 A SE 0201544A SE 0201544 A SE0201544 A SE 0201544A SE 0201544 D0 SE0201544 D0 SE 0201544D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
compounds
thier
thier use
Prior art date
Application number
SE0201544A
Other languages
English (en)
Swedish (sv)
Inventor
Bjoern Nilsson
Erik Ringberg
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to SE0201544A priority Critical patent/SE0201544D0/xx
Publication of SE0201544D0 publication Critical patent/SE0201544D0/xx
Priority to BR0310077-4A priority patent/BR0310077A/pt
Priority to CNB038112493A priority patent/CN1329389C/zh
Priority to SI200330377T priority patent/SI1506185T1/sl
Priority to HK06103395.9A priority patent/HK1084941B/xx
Priority to KR1020047018539A priority patent/KR20050026702A/ko
Priority to PT03725958T priority patent/PT1506185E/pt
Priority to DK03725958T priority patent/DK1506185T3/da
Priority to EA200401526A priority patent/EA007543B1/ru
Priority to ES03725958T priority patent/ES2263971T3/es
Priority to AT03725958T priority patent/ATE327229T1/de
Priority to MXPA04011437A priority patent/MXPA04011437A/es
Priority to CA002483619A priority patent/CA2483619A1/en
Priority to ZA200408975A priority patent/ZA200408975B/en
Priority to YU99804A priority patent/RS99804A/sr
Priority to EP03725958A priority patent/EP1506185B1/en
Priority to NZ536409A priority patent/NZ536409A/en
Priority to PCT/SE2003/000795 priority patent/WO2003097636A1/en
Priority to JP2004505369A priority patent/JP4865221B2/ja
Priority to DE60305484T priority patent/DE60305484T2/de
Priority to AU2003228196A priority patent/AU2003228196B2/en
Priority to US10/440,011 priority patent/US7229997B2/en
Priority to IL16497404A priority patent/IL164974A0/xx
Priority to NO20045486A priority patent/NO20045486L/no
Priority to CY20061101170T priority patent/CY1105162T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
SE0201544A 2002-05-17 2002-05-17 Novel compounds and thier use SE0201544D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0201544A SE0201544D0 (sv) 2002-05-17 2002-05-17 Novel compounds and thier use
US10/440,011 US7229997B2 (en) 2002-05-17 2003-05-16 Compounds and their use
AT03725958T ATE327229T1 (de) 2002-05-17 2003-05-16 Verbindungen und deren verwendung als 5-ht inhibitore
CA002483619A CA2483619A1 (en) 2002-05-17 2003-05-16 Novel compounds and their use
SI200330377T SI1506185T1 (sl) 2002-05-17 2003-05-16 Spojine in njihova uporaba kot inhibitorji 5-HT
HK06103395.9A HK1084941B (en) 2002-05-17 2003-05-16 Compounds and their use
KR1020047018539A KR20050026702A (ko) 2002-05-17 2003-05-16 신규한 화합물 및 이의 용도
PT03725958T PT1506185E (pt) 2002-05-17 2003-05-16 Compostos novos e sua utilizacao
DK03725958T DK1506185T3 (da) 2002-05-17 2003-05-16 Forbindelser og deres anvendelse som 5-HT-inhibitorer
EA200401526A EA007543B1 (ru) 2002-05-17 2003-05-16 Производные 4-(3-трифторметилпиридин-5-ил)пиперазина, фармацевтическая композиция, способы их получения и применение
ES03725958T ES2263971T3 (es) 2002-05-17 2003-05-16 Compuestos y su uso como inhibidores de 5-ht.
BR0310077-4A BR0310077A (pt) 2002-05-17 2003-05-16 Novos compostos e sua utilização
MXPA04011437A MXPA04011437A (es) 2002-05-17 2003-05-16 Nuevos compuestos y su uso.
CNB038112493A CN1329389C (zh) 2002-05-17 2003-05-16 化合物和它们的用途
ZA200408975A ZA200408975B (en) 2002-05-17 2003-05-16 Novel compounds are their use.
YU99804A RS99804A (sr) 2002-05-17 2003-05-16 Nova jedinjenja i njihova upotreba
EP03725958A EP1506185B1 (en) 2002-05-17 2003-05-16 Compounds and their use as inhibitors of 5-ht
NZ536409A NZ536409A (en) 2002-05-17 2003-05-16 New piperazine compounds and their use in the treatment of serotonin-related disorders
PCT/SE2003/000795 WO2003097636A1 (en) 2002-05-17 2003-05-16 Novel compounds and their use
JP2004505369A JP4865221B2 (ja) 2002-05-17 2003-05-16 新規化合物とそれらの使用
DE60305484T DE60305484T2 (de) 2002-05-17 2003-05-16 Verbindungen und deren verwendung als 5-ht inhibitoren
AU2003228196A AU2003228196B2 (en) 2002-05-17 2003-05-16 Novel compounds and their use
IL16497404A IL164974A0 (en) 2002-05-17 2004-11-01 Novel compounds and their use
NO20045486A NO20045486L (no) 2002-05-17 2004-12-16 Nye forbindelser og deres anvendelse
CY20061101170T CY1105162T1 (el) 2002-05-17 2006-08-23 Ενωσεις και η χρηση τους ως αναστολεις 5-ητ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201544A SE0201544D0 (sv) 2002-05-17 2002-05-17 Novel compounds and thier use
US41003802P 2002-09-12 2002-09-12

Publications (1)

Publication Number Publication Date
SE0201544D0 true SE0201544D0 (sv) 2002-05-17

Family

ID=29552452

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201544A SE0201544D0 (sv) 2002-05-17 2002-05-17 Novel compounds and thier use

Country Status (24)

Country Link
US (1) US7229997B2 (enExample)
EP (1) EP1506185B1 (enExample)
JP (1) JP4865221B2 (enExample)
KR (1) KR20050026702A (enExample)
CN (1) CN1329389C (enExample)
AT (1) ATE327229T1 (enExample)
AU (1) AU2003228196B2 (enExample)
BR (1) BR0310077A (enExample)
CA (1) CA2483619A1 (enExample)
CY (1) CY1105162T1 (enExample)
DE (1) DE60305484T2 (enExample)
DK (1) DK1506185T3 (enExample)
EA (1) EA007543B1 (enExample)
ES (1) ES2263971T3 (enExample)
IL (1) IL164974A0 (enExample)
MX (1) MXPA04011437A (enExample)
NO (1) NO20045486L (enExample)
NZ (1) NZ536409A (enExample)
PT (1) PT1506185E (enExample)
RS (1) RS99804A (enExample)
SE (1) SE0201544D0 (enExample)
SI (1) SI1506185T1 (enExample)
WO (1) WO2003097636A1 (enExample)
ZA (1) ZA200408975B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
WO2006022420A1 (ja) * 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
KR101286569B1 (ko) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 신규 약제
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
DK2079732T3 (da) * 2006-05-29 2012-01-23 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazin, dets salte og solvater og dets anvendelse som histamin H3-receptorantagonister
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
AR063373A1 (es) * 2006-10-24 2009-01-21 Wyeth Corp Derivados de benzodioxano y sus usos
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
SI2148873T1 (sl) 2007-04-23 2013-01-31 Janssen Pharmaceutica, N.V. Derivati 4-alkoksipiridazina kot antagonisti receptorja dopamina 2 s hitro disociacijo
ES2400710T3 (es) 2007-04-23 2013-04-11 Janssen Pharmaceutica, N.V. Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
ES2398625T3 (es) 2008-07-03 2013-03-20 Janssen Pharmaceutica N.V. 6-(1-Piperazinil)-piritazinas sustituidas como antagonistas de receptores 5-HT6
US8895562B2 (en) 2008-07-31 2014-11-25 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
AR077094A1 (es) 2009-06-15 2011-08-03 Takeda Pharmaceutical Derivados de pirazinooxazepina, composiciones farmaceuticas y su uso en el tratamiento de un sintoma del aparato urinario inferior, obesidad y/o prolapso de organos
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2013010679A1 (en) 2011-07-15 2013-01-24 Novartis Ag Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
TW202504600A (zh) * 2023-07-04 2025-02-01 大陸商杭州中美華東製藥有限公司 Glp1r激動劑及其中間體的製備方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078063A (en) * 1976-09-24 1978-03-07 Merck & Co., Inc. Piperazinylpyridines
EP0370560B1 (en) * 1988-11-24 1994-01-12 Akzo Nobel N.V. Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines
EP0580465A1 (fr) * 1992-06-25 1994-01-26 Sanofi Nouvelle utilisation thérapeutique d'hétérocyclyl-pipérazines comme 5-HT3 agonistes et nouveaux dérivés
JPH0665203A (ja) * 1992-06-25 1994-03-08 Elf Sanofi ピペラジンのヘテロ環誘導体
SE9202265D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel- pyridyl and pyrimidylpiperazine derivatives
JPH0797370A (ja) * 1993-09-29 1995-04-11 Asahi Chem Ind Co Ltd ２−アルコキシピラジン誘導体およびその用途
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
KR100846339B1 (ko) * 2000-11-20 2008-07-15 바이오비트럼 에이비(피유비엘) 세로토닌 5ｈｔ-2 수용체의 아고니스트 또는안타고니스트로서의 피페라지닐피라진 화합물
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
EP1213017A3 (en) * 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes

Also Published As

Publication number Publication date
EP1506185B1 (en) 2006-05-24
EP1506185A1 (en) 2005-02-16
DE60305484T2 (de) 2006-11-09
WO2003097636A1 (en) 2003-11-27
JP2005529926A (ja) 2005-10-06
CN1701068A (zh) 2005-11-23
KR20050026702A (ko) 2005-03-15
EA200401526A1 (ru) 2005-04-28
ES2263971T3 (es) 2006-12-16
US20030232814A1 (en) 2003-12-18
CY1105162T1 (el) 2010-03-03
HK1084941A1 (en) 2006-08-11
DE60305484D1 (de) 2006-06-29
NZ536409A (en) 2007-11-30
PT1506185E (pt) 2006-10-31
CN1329389C (zh) 2007-08-01
ATE327229T1 (de) 2006-06-15
CA2483619A1 (en) 2003-11-27
IL164974A0 (en) 2005-12-18
SI1506185T1 (sl) 2006-10-31
US7229997B2 (en) 2007-06-12
AU2003228196A1 (en) 2003-12-02
MXPA04011437A (es) 2005-02-17
ZA200408975B (en) 2005-11-14
DK1506185T3 (da) 2006-10-02
NO20045486L (no) 2005-02-02
EA007543B1 (ru) 2006-10-27
RS99804A (sr) 2006-12-15
AU2003228196B2 (en) 2009-12-17
BR0310077A (pt) 2005-02-22
JP4865221B2 (ja) 2012-02-01

Similar Documents

Publication Publication Date Title
SE0201544D0 (sv) Novel compounds and thier use
IS6658A (is) Ný efnasambönd
SE0302760D0 (sv) New compounds
SE0001899D0 (sv) New compounds
PT1263725E (pt) Novos compostos
SE0103836D0 (sv) Novel compounds
SE0300119D0 (sv) Novel compounds
ATE316083T1 (de) Adamantanderivate
SE0300480D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
ATE386725T1 (de) Heterocyclylverbindungen
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200604197A (en) New compounds
NO20020282D0 (no) Nytt difenylpiperidinderivat
SE0101038D0 (sv) Novel compounds
DE602004031410D1 (de) Inden derivate als pharmazeutika
SE0203303D0 (sv) Novel Compounds
SE0303280D0 (sv) Novel compounds
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0203300D0 (sv) Novel Compounds
SE0302755D0 (sv) Novel compounds
SE0202693D0 (sv) Compounds
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
SE0403118D0 (sv) New compounds 2
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern